45 related articles for article (PubMed ID: 8707262)
1. Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines.
Ogasawara S; Yano H; Iemura A; Hisaka T; Kojiro M
Hepatology; 1996 Jul; 24(1):198-205. PubMed ID: 8707262
[TBL] [Abstract][Full Text] [Related]
2. Significance of basic fibroblast growth factor and fibroblast growth factor receptor protein expression in the formation of fibrotic focus in invasive ductal carcinoma of the breast.
Hasebe T; Imoto S; Ogura T; Mukai K
Jpn J Cancer Res; 1997 Sep; 88(9):877-85. PubMed ID: 9369936
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous binding of bFGF to both FGFR and integrin maintains properties of primed human induced pluripotent stem cells.
Cheng YS; Taniguchi Y; Yunoki Y; Masai S; Nogi M; Doi H; Sekiguchi K; Nakagawa M
Regen Ther; 2024 Mar; 25():113-127. PubMed ID: 38226057
[TBL] [Abstract][Full Text] [Related]
4. Investigating cellular dynamics in tunicates.
Cota CD
Genesis; 2023 Nov; 61(6):e23574. PubMed ID: 37984368
[No Abstract] [Full Text] [Related]
5. Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges.
Kamal MA; Mandour YM; Abd El-Aziz MK; Stein U; El Tayebi HM
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080304
[TBL] [Abstract][Full Text] [Related]
6. Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma.
Wang Y; Song T; Li K; Liu H; Han Y; Xu T; Cao F; Li Y; Yu Y
World J Surg Oncol; 2022 Jul; 20(1):236. PubMed ID: 35840985
[TBL] [Abstract][Full Text] [Related]
7. ONECUT2 facilitates hepatocellular carcinoma metastasis by transcriptionally upregulating FGF2 and ACLY.
Liu D; Zhang T; Chen X; Zhang B; Wang Y; Xie M; Ji X; Sun M; Huang W; Xia L
Cell Death Dis; 2021 Nov; 12(12):1113. PubMed ID: 34839358
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma.
Le TBU; Vu TC; Ho RZW; Prawira A; Wang L; Goh BC; Huynh H
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321903
[TBL] [Abstract][Full Text] [Related]
9. New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma.
Mossenta M; Busato D; Baboci L; Cintio FD; Toffoli G; Bo MD
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31370258
[TBL] [Abstract][Full Text] [Related]
10. Locoregional and systemic therapy for hepatocellular carcinoma.
Gbolahan OB; Schacht MA; Beckley EW; LaRoche TP; O'Neil BH; Pyko M
J Gastrointest Oncol; 2017 Apr; 8(2):215-228. PubMed ID: 28480062
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional Induction of Periostin by a Sulfatase 2-TGFβ1-SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma.
Chen G; Nakamura I; Dhanasekaran R; Iguchi E; Tolosa EJ; Romecin PA; Vera RE; Almada LL; Miamen AG; Chaiteerakij R; Zhou M; Asiedu MK; Moser CD; Han S; Hu C; Banini BA; Oseini AM; Chen Y; Fang Y; Yang D; Shaleh HM; Wang S; Wu D; Song T; Lee JS; Thorgeirsson SS; Chevet E; Shah VH; Fernandez-Zapico ME; Roberts LR
Cancer Res; 2017 Feb; 77(3):632-645. PubMed ID: 27872089
[TBL] [Abstract][Full Text] [Related]
12. Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma.
Chauhan R; Lahiri N
Biomark Cancer; 2016; 8(Suppl 1):37-55. PubMed ID: 27398029
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma.
Watari K; Nishitani A; Shibata T; Noda M; Kawahara A; Akiba J; Murakami Y; Yano H; Kuwano M; Ono M
Oncotarget; 2016 Jul; 7(30):47403-47417. PubMed ID: 27329724
[TBL] [Abstract][Full Text] [Related]
14. (125)I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma.
Hu PH; Pan LH; Wong PT; Chen WH; Yang YQ; Wang H; Xiang JJ; Xu M
World J Gastroenterol; 2016 Jun; 22(21):5033-41. PubMed ID: 27275095
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of protein kinase C by isojacareubin suppresses hepatocellular carcinoma metastasis and induces apoptosis in vitro and in vivo.
Yuan X; Chen H; Li X; Dai M; Zeng H; Shan L; Sun Q; Zhang W
Sci Rep; 2015 Aug; 5():12889. PubMed ID: 26245668
[TBL] [Abstract][Full Text] [Related]
16. Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma.
Kudo M
World J Gastroenterol; 2012 Nov; 18(42):6005-17. PubMed ID: 23155330
[TBL] [Abstract][Full Text] [Related]
17. A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts.
Wang L; Park H; Chhim S; Ding Y; Jiang W; Queen C; Kim KJ
Mol Cancer Ther; 2012 Apr; 11(4):864-72. PubMed ID: 22351746
[TBL] [Abstract][Full Text] [Related]
18. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets.
Yang JD; Nakamura I; Roberts LR
Semin Cancer Biol; 2011 Feb; 21(1):35-43. PubMed ID: 20946957
[TBL] [Abstract][Full Text] [Related]
19. Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice.
Kudo M
Int J Clin Oncol; 2010 Jun; 15(3):242-55. PubMed ID: 20509038
[TBL] [Abstract][Full Text] [Related]
20. Heparanase and hepatocellular carcinoma: promoter or inhibitor?
Dong S; Wu XZ
World J Gastroenterol; 2010 Jan; 16(3):306-11. PubMed ID: 20082475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
